Surveillance of:
• Adenomatous polyps: 13.5 percent
• Colorectal cancer: 2 percent
• Ulcerative colitis: 0.9 percent
• Crohn’s disease: 0.6 percent
• Established Crohn’s disease: 0.2 percent
• Established ulcerative colitis: 0.2 percent
Screening:
• Routine risk only: 21.6 percent
• Family history of colorectal cancer: 12.1 percent
• Family history of polyps: 2.8 percent
Symptoms:
• Bleeding: 29.7 percent
• Irritable bowel syndrome: 18.2 percent
• Hematochezia: 17.9 percent
• Abdominal pain/bloating: 9.1 percent
• Diarrhea: 7.6 percent
• Positive fecal occult blood test: 7.2 percent
• Change in bowel habits: 7.1 percent
• Anemia: 5.7 percent
• Constipation: 5.4 percent
• Weight loss: 1.6 percent
• Melena: 0.7 percent
• Iron deficiency without anemia: 0.3 percent
Follow-up diagnosis of:
• Polyp found in flexible sigmoidoscopy: 1.5 percent
• Abnormal study: 1 percent
• History of non-GI cancer: 0.8 percent
• Suspected IBS: 0.5 percent
• Polyp found in barium enema: 0.2 percent
• Polyp found in previous colonoscopy: 0.2 percent
Other:
• 6.5 percent
More Articles on Gastroenterology:
Screening Efforts Show Results, Colorectal Cancer Rates Drop 30%
AGA Launches Observational Research Device Registries
6 Gastroenterologists on Improving Efficiency in the Field
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.